Ferring Pharmaceuticals presents data on Rekovelle fertility drug
The results of two studies on the fertility drug Rekovelle showing the drug’s efficacy and safety during in vitro fertilization were presented at the European Society of Human Reproduction and Embryology’s 33rd annual meeting in Geneva, Switzerland.
Manufactured by Swiss-based Ferring Pharmaceuticals, Rekovelle (follitropin delta) is a synthetic follicle stimulating hormone, a class of substances that, when naturally produced by a patient’s pituitary gland, help regulate fertility in both women and men. For the studies presented in Geneva, the subjects were women undergoing in vitro fertilization procedures, a Ferring release said.
The studies indicated Rekovelle produced a similar rate of live births compared to patients receiving an older medicine, follitropin alfa. The studies also proved Rekovelle was safe in patients with elevated levels of anti-Mullerian hormone (AMH) .
“Rekovelle’s individualized dosing regimen, based on a patient’s AMH level and body weight, provides clinicians with a consistent, evidence-based approach to personalizing treatment for their patients,” Ferring Executive Vice President and Chief Science Officer Per Falk, said in the release. “These new Rekovelle analyses add further evidence for a personalized approach to fertility treatment for patients.”
Organizations in this story
Ferring Pharmaceuticals FERRING INTERNATIONAL CENTER S.A. CH. DE LA VERGOGNAUSAZ 50 1162 SAINT-PREX SWITZERLAND